NCT06914609View on ClinicalTrials.gov

REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome

PHASE3RecruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

April 30, 2030

Conditions
Angelman Syndrome
Interventions
DRUG

ION582

ION582 will be administered by IT injection.

DRUG

Placebo

ION582 matching placebo will be administered by IT injection.

Trial Locations (9)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

20011

RECRUITING

Children's National Hospital, Washington D.C.

27510

RECRUITING

University of North Carolina at Chapel Hill School of Medicine, Carrboro

33155

RECRUITING

Nicklaus Children's Hospital, Miami

60612

RECRUITING

Rush University Medical Center, Chicago

64108

RECRUITING

Children's Mercy, Kansas City

80045

RECRUITING

Colorado Children's Hospital Research Institute, Aurora

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

92123

RECRUITING

Rady Children's Hospital, San Diego

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY